Large GLP-1 Drug Review Takes Closer Look at Risks, Rewards
Moderate- to high-quality evidence from an umbrella review on non-cardiometabolic outcomes reinforced links between GLP-1 therapies and risks…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…